Published : 27 Dec 2021
Aagami are proud to announce that their Current Japanese client has given a new assignment, to seek partnerships for their other assets in the pipeline. The contract is signed and the assignment will start in the first week of January 2022.
The reason for the new assignment is the client’s satisfaction and trust that Aagami has secured, while delivering an earlier assignment.
The Japanese client is focused on addressing unmet needs and bringing innovative transdermal drugs with their proprietary drug platform formulations and microneedle array technologies. The client does not intend to commercialize the assets themselves in the US and other outside-Japan geographies. Their strategy is to out-license the assets to a company with strong sales presence in the geographies of interest such as the US.
The therapy areas addressed by the clients assets include Moderate-Severe Pain, Chronic Pain, Neuropathic Pain, and Alzheimer’s Disease.
Aagami are excited to add and deliver partnering of client’s 3 more pipeline assets to the partnering assignment for US and other geographies.